Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity
(Q45788517)
scientific article published on November 1, 1995
scientific article published on November 1, 1995
Language: